Abstract
Diabetic retinopathy is regarded as a common manifestation of diabetes mellitus, being a prominent cause of visual impairment and blindness. This microvascular complication is marked by the appearance of microaneurysms, elevated vascular permeability, capillary blockage, and proliferation of neovasculature. The etiology behind retinopathy is ambiguous and the efficacy of current treatment strategies is minimal. Early diagnosis of this complication using a biomarker with high sensitivity and specificity is very essential for providing better therapeutic strategies. The current available therapeutic options are limited with various adverse effects. Laser treatment is not beneficial in all the situations, economic constraints being the major challenge. Surgical interventions are employed when pharmacotherapy and laser treatment fail. New pharmacological treatments are becoming a necessity for treating the condition. This review highlights the use of various diagnostic tools, emerging biomarkers for early detection of diabetic retinopathy, pathological mechanisms associated with the disease, current therapeutic approaches used and future strategies for more enhanced treatment options and more potent pharmacological actions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
References
Al-Shabrawey M, Smith S (2010) Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA J 1(1):56–72
Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274:23463–23467. https://doi.org/10.1074/jbc.274.33.23463
Arevalo JF, Garcia-Amaris RA (2009) Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev 5(1):39–46. https://doi.org/10.2174/157339909787314121
Balguri SP, Adelli GR, Janga KY, Bhagav P, Majumdar S (2017) Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol. Int. J. Pharm 529(1–2):32–43
Barber AJ, Lieth E, Khin SA, Antonetti DA, BuchananAG GTW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Investig 102:783–791. https://doi.org/10.1172/jci2425
Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245–251. https://doi.org/10.1001/archophthalmol.2008.610
Bek T (2017) Diameter changes of retinal vessels in diabetic retinopathy. Curr Diabetes Rep 17(10):82. https://doi.org/10.1007/s11892-017-0909-9
Beltramo E, Porta M (2013) Pericyte loss in diabetic retinopathy: mechanisms and consequences. Curr Med Chem 20:3218–3225. https://doi.org/10.2174/09298673113209990022
Bhatia S, Babbar R, Zehravi M, Singh B, Chandel P, Hasan MM, Arora R, Gill NS, Sindhu RK, Ahmad Z, Khan FS (2022) Angiogenic footprints in diabetic retinopathy: opportunities for drug development. Biotechnol Genet Eng Rev 11:1–25. https://doi.org/10.1080/02648725.2022.2102880
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, MEAD Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–14
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625. https://doi.org/10.2337/diabetes.54.6.1615
Brownrigg JR, Schaper NC, Hinchliffe RJ (2015) Diagnosis and assessment of peripheral arterial disease in the diabetic foot. Diabet Med 32(6):738–747. https://doi.org/10.1111/dme.12749
Bursell SE, King GL (1999) Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract 45:169–182. https://doi.org/10.1016/s0168-8227(99)00047-9
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119(10):2125–2132. https://doi.org/10.1016/j.ophtha.2012.04.030
Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J (2011) Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 118(4):626–35
Chen C, Shah CP (2011) Review of therapeutic advances in diabetic retinopathy. TherAdvEndocrinolMetab 2(1):39–53
Chung J, Park YH, Lee YC (2008) The effect of Nd: YAG laser membranotomy and intravitreal tissue plasminogen activator with gas on massive diabetic premacular hemorrhage. Ophthalmic Surg Lasers Imaging 39:114–120. https://doi.org/10.3928/15428877-20080301-06
Corcóstegui B, Durán S, González-Albarrán MO, Hernández C, Ruiz-Moreno JM, Salvador J, Udaondo P, Simó R (2017) Update on diagnosis and treatment of diabetic retinopathy: a consensus guideline of the working group of Ocular Health (Spanish society of diabetes and spanish vitreous and retina society). J. Ophthalmol 2017(1):10
Deshpande AD, Harris-Hayes M, Schootman M (2008) Epidemiology of diabetes and diabetes-related complications. PhysTher 88(11):1254–1264. https://doi.org/10.2522/ptj.20080020
Devi KS, Sasya M, Krishnan UM (2020) Emerging vistas on electrochemical detection of diabetic retinopathy biomarkers. TrACTren in Analy Chem. https://doi.org/10.1016/j.trac.2020.115838
Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Rückert R, Sandbrink R, Stein D, Yang K (2011) The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 118(9):1819–26
Duh EJ, Sun JK, Stitt AW (2017) Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI insight 2(14):e93751
Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW (2008) Importance of pericytes and mechanisms of Pericyte loss during diabetes retinopathy. Diabetes Obes Metab 10:53–63. https://doi.org/10.1111/j.1463-1326.2007.00795.x
El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K (2004) Expression of apoptosis markers in the retinas of human subjects with diabetes. Investig Ophthalmol vis Sci 45:2760–2766. https://doi.org/10.1167/iovs.03-1392
Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL III, Friedman SM, Glassman AR, Miller KM, Scott IU (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6):1064–1077. https://doi.org/10.1016/j.ophtha.2010.02.031
Elsawy MF, Badawi N, Khairy HA (2013) Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clin Ophthalmol (auckland, NZ) 7:1245. https://doi.org/10.2147/opth.s39188
Fijalkowski N, Moshfeghi DM (2013) New laser technologies for diabetic retinopathy. Curr Ophthalmol Rep 1(3):134–143. https://doi.org/10.1007/s40135-013-0017-1
G Schwartz S, W Flynn H (2011) Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 12(3):347–351
Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ (2015) Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137–2146. https://doi.org/10.1001/jama.2015.15217
Huang H, He J, Johnson DK, Wei Y, Liu Y, Wang S, Lutty GA, Duh EJ, Carmeliet P, Semba RD (2015) Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition. Diabetes 64(1):200–212
Iglicki M, Zur D, Busch C, Okada M, Loewenstein A (2018) Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study.’ Acta Diabetol 55(6):541–547. https://doi.org/10.1007/s00592-018-1117-z
Ip MS, Domalpally A, Sun JK, Ehrlich JS (2015) Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 122(2):367–374. https://doi.org/10.1016/j.ophtha.2014.08.048
Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O’Neal DN, Januszewski AS (2015) Biomarkers in diabetic retinopathy. Rev Diabet Stud 12(1–2):159
Ji H, Yi Q, Chen L, Wong L, Liu Y, Xu G, Zhao J, Huang T, Li B, Yang Y, Li W (2020) Circulating miR-3197 and miR-2116-5p as novel biomarkers for diabetic retinopathy. ClinicaChimicaActa 501:147–153. https://doi.org/10.1016/j.cca.2019.10.036
Jonas JB (2007) (2007) Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol 39:96–110. https://doi.org/10.1159/000098502
Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. Faseb J 18:1450–1452. https://doi.org/10.1096/fj.03-1476fje
Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades C, Kirchhof B (2003) Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. Faseb J 17:76–78. https://doi.org/10.1096/fj.02-0157fje
Kaštelan S, Orešković I, Bišćan F, Kaštelan H, Gverović Antunica A (2020) Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Med 30(3):385–99
Kasza M, Meleg J, Várdai J, Nagy B, Szalai E, Damjanovich J, Csutak A, Ujhelyi B, Nagy V (2017) Plasma E-selectin levels can play a role in the development of diabetic retinopathy. Graefe’s Arch. Clin. Exp. Ophthalmol 255:25–30
Kato M, Arce L, Wang M, Putta S, Lanting L, Natarajan R (2011) A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int 80(4):358–368. https://doi.org/10.1038/ki.2011.43
Khan R, Ooi XY, Parvus M, Valdez L, Tsin A (2020) Advanced glycation end products: formation, role in diabetic complications, and potential in clinical applications. Eye Foot Diabetes 19:3. https://doi.org/10.5772/intechopen.89408
Kim HW, Kim JL, Lee HK, Hur DY, Yun IH, Kim SD (2009) Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr Eye Res 34(11):976–987. https://doi.org/10.3109/02713680903249913
Knickelbein JE, Abbott AB, Chew EY (2016) Fenofibrate and diabetic retinopathy. Curr Diabetes Rep 16(10):1–6. https://doi.org/10.1007/s11892-016-0786-7
Koleva-Georgieva DN, Sivkova NP, Terzieva D (2011) Serum inflammatory cytokines IL- 1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med 53:44–50. https://doi.org/10.2478/v10153-010-0036-8
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247–2254. https://doi.org/10.1016/j.ophtha.2014.05.006
Kowluru RA, Chan PS (2007) Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007:43603. https://doi.org/10.1155/2007/43603
Krishnamoorthy R, Kaliaperumal R, Venkatachalam R, Poovitha R, Rajagopalan G (2017) Apolipoproteins an early and better diagnostic marker for diabetic retinopathy. J ClinDiagn Res. https://doi.org/10.4102/aveh.v77i1.430
Lang GE (2007) Optical coherence tomography findings in diabetic retinopathy. Dev Ophthalmol 39:31–47. https://doi.org/10.1159/000098498
Lattanzio R, Cicinelli MV, Bandello F (2017) Intravitreal steroids in diabetic macular edema. Dev Ophthalmol 60:78–90. https://doi.org/10.1159/000459691
Li J, Paulus YM (2018) Advances in retinal laser therapy. Int. J. Ophthalmol. Res 4(1):259
Liu C, Chen G, Bentley AR, Doumatey A, Zhou J, Adeyemo A, Yang J, Rotimi C (2019) Genome-wide association study for proliferative diabetic retinopathy in Africans. NPJ genom. med 4(1):1–7
Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR (2020) The evolving treatment of diabetic retinopathy. Clin Ophthalmol 14:653
Martinez B, Peplow PV (2019) MicroRNAs as biomarkers of diabetic retinopathy and disease progression. Neural Regen Res 14(11):1858. https://doi.org/10.4103/1673-5374.259602
Mathebula SD (2018) Biochemical changes in diabetic retinopathy triggered by hyperglycaemia: a review Afr. Vis. Eye Health 77(1):1–7
Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y (2005) Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol vis Sci 46(3):1062–1068. https://doi.org/10.1167/iovs.04-0761
Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med 361(1):40–51
Medić A, Jukić T, Matas A, Vukojević K, Sapunar A, Znaor L (2017) Effect of preoperative topical diclofenac on intraocular interleukin-12 concentration and macular edema after cataract surgery in patients with diabetic retinopathy: a randomized controlled trial. Croat Med J 58(1):49–55. https://doi.org/10.3325/cmj.2017.58.49
Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, Peto T, Hykin P (2010) Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 30(5):781–786. https://doi.org/10.1097/iae.0b013e3181d2f145
Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836–10841. https://doi.org/10.1073/pnas.96.19.10836
ModernOptometry (2019) The Four Stages of Diabetic Retinopathy. Accessed 19 April 2021 https://modernod.com/articles/2019-june/the-four-stages-of-diabeticretinopathy
Mohamed Q, Gillies MC, Wong TY (2007) Management of diabetic retinopathy: a systematic review. JAMA 298(8):902–916. https://doi.org/10.1001/jama.298.8.902
Munir WM, Pulido JS, Sharma MC, Buerk BM (2005) Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol 40(5):598–604. https://doi.org/10.1016/s0008-4182(05)80052-3
Nadri G, Saxena S, Mahdi AA, Kaur A, Ahmad M, Garg P, Meyer CH (2019) Serum vitamin D is a biomolecular biomarker for proliferative diabetic retinopathy. Int J Retina Vitreous 5(1):1–5
Nagpal D, Panda SN, Malarvel M, Pattanaik PA, Khan MZ (2022) A review of diabetic retinopathy: datasets, approaches, evaluation metrics and future trends. J King Saud Univ Comput Inf Sci 34(9):7138–52
Naruse K, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T, Kato K, Kasuya Y, Miwa K, Hotta N (2000) Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res 71:309–315. https://doi.org/10.1006/exer.2000.0882
Omar AF, Silva PS, Sun JK (2013) Genetics of diabetic retinopathy. Semin Ophthalmol 28(5–6):337–346. https://doi.org/10.3109/08820538.2013.825287
Park YG, Roh YJ (2016) New diagnostic and therapeutic approaches for preventing the progression of diabetic retinopathy. J Diabetes Res. https://doi.org/10.1155/2016/1753584
Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA (2005) Angiopoietin concentrations in diabetic retinopathy. Br. J. Ophthalmol 89:480–483
Peng JJ, Xiong SQ, Ding LX, Peng J, Xia XB (2019) Diabetic retinopathy: focus on NADPH oxidase and its potential as therapeutic target. Eur J Pharmacol 853:381–387. https://doi.org/10.1016/j.ejphar.2019.04.038
Phillips KC, Clarke-Farr PC, Matsha TE, Meyer D (2018) Biomarkers as a predictor for diabetic retinopathy risk and management: a review. African vis Eye Health 77(1):1–5. https://doi.org/10.4102/aveh.v77i1.430
Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK (2011) Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic Retinopathy candesartan trials. Diabetologia 54(6):1298–1303. https://doi.org/10.1007/s00125-010-2040-1
Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP (2004) Insulin like growth factor I plays a pathogenetic role in diabetic retinopathy. Am. J. Pathol 165:457–469
Puglia C, Santonocito D, Ostacolo C, Maria Sommella E, Campiglia P, Carbone C, Drago F, Pignatello R, Bucolo C (2020) Ocular formulation based on palmitoylethanolamide-loaded nanostructured lipid carriers: technological and pharmacological profile. Nanomaterials 10(2):287
Qi HJ, Jin EZ, Zhao MW (2019) One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data. Int J Ophthalmol 12(1):51
Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Degli Esposti S, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130(8):972–979. https://doi.org/10.1016/j.ophtha.2014.07.002
Rajpoot K (2019) Solid lipid nanoparticles: a promising nanomaterial in drug delivery. Curr Pharm Des 25(37):3943–3959. https://doi.org/10.2174/1381612825666190903155321
Reddy MA, Tak Park J, Natarajan R (2013) Epigenetic modifications in the pathogenesis of diabetic nephropathy. SeminNephrol 33(4):341–353. https://doi.org/10.1016/j.semnephrol.2013.05.006
Rousseau S, Houle F, Landry J, Huot J (1997) p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15:2169–2177. https://doi.org/10.1038/sj.onc.1201380
Safi SZ, Qvist R, Kumar S, Batumalaie K, Ismail IS (2014) Molecular mechanisms of diabetic retinopathy, general preventive strategies and novel therapeutic targets. Biomed Res Int. https://doi.org/10.1155/2014/801269
Santos KG, Crispim D, Canani LH (2012) Relationship of endothelial nitric oxide synthase (eNOS) gene polymorphisms with diabetic retinopathy in Caucasians with type 2 diabetes. Ophthalmic Genet 33(1):23–27. https://doi.org/10.3109/13816810.2011.620057
Sasaki M, Ozawa Y, Kurihara T, Kubota S, Yuki K, Noda K, Kobayashi S, Ishida S, Tsubota K (2010) Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 53:971–979. https://doi.org/10.1007/s00125-009-1655-6
Scalbert A, Johnson IT, Saltmarsh M (2005) Polyphenols: antioxidants and beyond. Am J ClinNutr 81(1):215S-S217. https://doi.org/10.1093/ajcn/81.1.215s
Schroder S, Palinski W, Schmid-Schonbein GW (1991) Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139:81–100
Selvaraj K, Kuppusamy G, Krishnamurthy J, Mahalingam R, Singh SK, Gulati M (2019) Repositioning of itraconazole for the management of ocular neovascularization through surface-modified nanostructured lipid carriers. Assay Drug Dev Technol 17(4):178–190. https://doi.org/10.1089/adt.2018.898
Semeraro F, Morescalchi F, Cancarini A, Russo A, Rezzola S, Costagliola C (2019) Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. Diabetes Metab 45(6):517–527. https://doi.org/10.1016/j.diabet.2019.04.002
Sharma DS, Wadhwa S, Gulati M, Kadukkattil Ramanunny A, Awasthi A, Singh SK, Khursheed R, Corrie L, Chitranshi N, Gupta VK, Vishwas S (2021) Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy. Expert Opin Drug Deliv 18(5):553–576. https://doi.org/10.1080/17425247.2021.1846518
Sharma I, Yadav KS, Mugale MN (2022) Redoxisome and diabetic retinopathy: pathophysiology and therapeutic Interventions. Pharmacol Res. https://doi.org/10.1016/j.phrs.2022.106292
Sharma T, Fong A, Lai TY, Lee V, Das S, Lam D (2016) Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Exp Ophthalmol 44(4):340–354. https://doi.org/10.1111/ceo.12752
Simó-Servat O, Simó R, Hernández C (2016) Circulating biomarkers of diabetic retinopathy: an overview based on physiopathology. J Diabetes Res 2016:1–13. https://doi.org/10.1155/2016/5263798
Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A, Staurenghi G, Cervantes GC, Alpern L, Modi S, Svoboda L (2017) Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies. Ophthalmology 124(6):776–85
Sirerol JA, Rodríguez ML, Mena S, Asensi MA, Estrela JM, Ortega AL (2016) Role of natural stilbenes in the prevention of cancer. Oxid. Med. Cell. Longev 2016(1):15
Sorrentino FS, Allkabes M, Salsini G, Bonifazzi C, Perri P (2016) The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy. Life Sci 162:54–59. https://doi.org/10.1016/j.lfs.2016.08.001
Starita C, Patel M, Katz B, Adamis AP (2007) Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol 39:122–148. https://doi.org/10.1159/000098504
Stewart MW (2016) Treatment of diabetic retinopathy: recent advances and unresolved challenges. World J Diabetes 7(16):333. https://doi.org/10.4239/wjd.v7.i16.333
Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y (2011) Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55:256–263. https://doi.org/10.1007/s10384-011-0004-8
Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R (2013) Pathophysiology of diabetic retinopathy. Int Sch Res Notices. https://doi.org/10.1155/2013/343560
Tatke A, Dudhipala N, Janga KY, Balguri SP, Avula B, Jablonski MM, Majumdar S (2019) In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials 9(1):33. https://doi.org/10.3390/nano9010033
Tien T, Zhang J, Muto T, Kim D, Sarthy VP, Roy S (2017) High glucose induces mitochondrial dysfunction in retinal muller cells: Implications for diabetic retinopathy. Investig. Ophthalmol. Vis. Sci 58:2915–2921
Ting DS, Tan KA, Phua V, Tan GS, Wong CW, Wong TY (2016) Biomarkers of Diabetic Retinopathy. Curntdiabet Repo 16(12):1–5. https://doi.org/10.1007/s11892-016-0812-9
Torok Z, Peto T, Csosz E, Tukacs E, Molnar A, Maros-Szabo Z, Berta A, Tozser J, Hajdu A, Nagy V, Domokos B (2013) Tear fluid proteomics multimarkers for diabetic retinopathy screening. BMC ophthalmology 13(1):1–8
Tuttolomondo A, Maida C, Pinto A (2015) Diabetic foot syndrome as a possible cardiovascular marker in diabetic patients. J Diabetes Res. https://doi.org/10.1155/2015/268390
U.S. National Library of Medicine (2021) ClinicalTrials.gov. Accessed 19 April 2021 https://www.clinicaltrials.gov/
UK Prospective Diabetes Study Group (1991) UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia 34:877–90
Vail D, Callaway NF, Ludwig CA, Saroj N, Moshfeghi DM (2019) Lipid-lowering medications are associated with lower risk of retinopathy and ophthalmic interventions among United States patients with diabetes. Am J Ophthalmol 207:378–384. https://doi.org/10.1016/j.ajo.2019.05.029
Wang L, Zhou X, Yin Y, Mai Y, Wang D, Zhang X (2019) Hyperglycemia induces neutrophil extracellular traps formation through an NADPH oxidase-dependent pathway in diabetic retinopathy. Front Immunol 9:3076. https://doi.org/10.3389/fimmu.2018.03076
Wang W, Lo AC (2018) Diabetic retinopathy: pathophysiology and treatments. Int. J. Mol. Sci 19(6):1816
Yun SH, Adelman RA (2015) Recent developments in laser treatment of diabetic retinopathy. Middle East Afr J Ophthalmol 22(2):157. https://doi.org/10.4103/0974-9233.150633
Zhang B, Chou Y, Zhao X, Yang J, Chen Y (2020) Early detection of microvascular impairments with optical coherence tomography angiography in diabetic patients without clinical retinopathy: a meta-analysis. Am J of Ophthalmol 222:226–237. https://doi.org/10.1016/j.ajo.2020.09.032
Zhou Y, Wang C, Shi K, Yin X (2018) Relationship between dyslipidemia and diabetic retinopathy: a systematic review and meta-analysis. Medicine 97(36):e12283
Acknowledgements
The authors are thankful to Chitkara University, Rajpura, Punjab for providing the necessary facilities during this work.
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
SB and TGS contributed to the ideation of the concept behind the review. Manuscript draft was written by AS, IG and DKL. Literature survey was conducted by PC. The manuscript was reviewed by SB, RSJ and AS. The manuscript was finalized by SB and TGS. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sood, A., Baishnab, S., Gautam, I. et al. Exploring various novel diagnostic and therapeutic approaches in treating diabetic retinopathy. Inflammopharmacol 31, 773–786 (2023). https://doi.org/10.1007/s10787-023-01143-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-023-01143-x